This organization files Form 990, which has no section for application policy. Its filings cannot say either way.
The latest filing we hold carries no statement about applications. That is not the same as closed: public-charity Form 990s have no field for it, and many foundations leave the section blank.
Grants paid by year
Total assets by year
Where the money went · FY2025
Form 990 splits expenses into program services, management and fundraising. The split is self-reported, and a grantmaker, a research institute and a direct-service nonprofit book the same work differently. A line the return does not carry reads "not available"; it is never counted as zero.
| Year | Form | Revenue | Expenses | Grants paid | Assets | Net assets |
|---|---|---|---|---|---|---|
| FY2025 | 990 | $7,559,812 | $7,077,785 | $849,999 | $15,271,954 | $13,081,885 |
| FY2024 | 990 | $5,670,792 | $5,078,413 | $710,000 | $13,552,735 | $11,704,240 |
| FY2023 | 990 | $3,555,325 | $3,580,103 | $370,000 | $12,011,651 | $10,611,110 |
| FY2022 | 990 | $4,388,529 | $3,790,735 | $789,999 | $11,363,951 | $10,032,823 |
| FY2021 | 990 | $3,840,681 | $3,008,153 | $425,000 | $12,076,757 | $10,858,739 |
| FY2020 | 990 | $3,577,214 | $2,477,510 | $310,545 | $10,606,667 | $9,734,054 |
Figures are as reported on the e-filed return, with no restatement. Fiscal years are the funder's own tax year, labelled by the calendar year the period ends in. A blank line means the return does not carry that figure; a real zero shows as $0. When an amended return replaces an original, every figure here uses the amended return. The original is not shown. Giving is what the funder actually paid out toward its charitable purpose in the year (qualifying distributions on Form 990-PF, charitable disbursements otherwise). Assets are what it holds; giving is what moves.
Recipient focus areas
Where recipients are
Based on the 30% of grant rows we could match to an organization record. The rest stay as reported. The IRS assigns the NTEE category when it grants exemption. It often reflects the original filing, not today's giving.
| Recipient | Purpose | Amount | Year | Source |
|---|---|---|---|---|
| University of PennsylvanniaPhiladelphia, PA | Preclinical models and biomarkers for predicting MuSK-CAART clinical outcomes | $300,000 | 2022 | |
Recipients are shown as the funder wrote them on the return. A recipient with a link was matched to an organization record; the rest stay as reported and are never guessed.
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| Robert Thomas | Chair | 8.00 | $0 |
| Adrejia Boutte | Secretary | 8.00 | $0 |
| Ani Maitra | Director | 4.00 | $0 |
| Justin Stachtiaris | Treasurer and Vice Chair |
From the officer list on the latest e-filed return. Compensation is as reported there; a blank means the return carries no figure.
| Yale UniversityNew Haven, CT |
| Defining new autoimmune mechanisms in seronegative MG |
| $300,000 |
| 2024 |
| George Washington University - MGNetWashington, DC | "CAPTURE-MG study (Clinical Procedures To Support Research in Myasthenia Gravis) | $250,000 | 2025 |
| Yale UniversityNew Haven, CT | Measuring AChR autoantibody effector functions in myasthenia gravis patients. | $225,000 | 2022 |
| American Brain FoundationMinneapolis, MN | Clinician Scientist Development Award in Myathenia Gravis | $159,999 | 2025 |
| American Brain FoundationMinneapolis, MN | Medical research | $159,999 | 2022 |
| DUKE UNIVERSITYDURHAM, NC | MEDICAL RESEARCH | $150,000 | 2020 |
| Yale UniversityNew Haven, CT | Novel mechanistic insights into the MuSK-specific autoantibody repertoire | $110,000 | 2024 |
| Univeristy of California San DiegoLa Jolla, CA | Purification of the acetylcholine receptor toward atomic-scale mechanisms underlying MG | $110,000 | 2023 |
| University of California DavisDavis, CA | AAV-mediated gene therapy for congenital myasthenia caused by recessive synaptotagmin 2 mutations. | $110,000 | 2023 |
| Boston Children's HospitalBoston, MA | Dissecting genetic determinants of dendritic cell dysfunction in myasthenia gravis | $110,000 | 2025 |
| Duke University School of MedicineErwin Square, NC | Deciphering Immunological Biomarkers in Myasthenia Gravis by Using Multiomics. | $110,000 | 2024 |
| The George Washington UniversityWashington, DC | Medical research | $110,000 | 2021 |
| Lankenau Institute for Medical ResearchWynnewood, PA | Medical research | $110,000 | 2021 |
| Uppsala University | Validating diagnostic and prognostic serum biomarkers for AChR antibody seropositive MG | $110,000 | 2024 |
| Mayo ClinicRochester, MN | The 3' untranslated region variants and therapeutic targets in congenital myasthenic syndrome genes | $100,000 | 2023 |
| Duke UniversityDurham, NC | Medical research | $75,000 | 2021 |
| University of California DavisWest Sacramento, CA | Medical research | $55,000 | 2021 |
| YALE UNIVERSITYNEW HAVEN, CT | MEDICAL RESEARCH | $55,000 | 2020 |
| University of MichiganAnn Arbor, MI | Advancing patient-centered care and research for ocular myasthenia gravis: Validation of a novel patient reported outcome measure | $55,000 | 2022 |
| UNIVERSITY OF VERMONTBURLINGTON, VT | MEDICAL RESEARCH | $55,000 | 2020 |
| The George Washington UniversityAshburn, VA | Dr Kaminski's MG Net Pilot Studies program | $50,000 | 2023 |
| The George Washington UniversityAshbum, VA | Medical research | $50,000 | 2021 |
| The George Washington UniversityAshbum, VA | Dr Kaminski's MG Net Pilot Studies program | $50,000 | 2024 |
| WASHINGTON UNIVERSITYWASHINGTON, DC | MEDICAL RESEARCH | $50,000 | 2020 |
| 8.00 |
| $0 |
| Callum Schjerning | Director | 4.00 | $0 |
| Clyde Hosein | Director | 4.00 | $0 |
| Erin Harrigan | Director (beg 10/25) | 4.00 | $0 |
| Kelly Gwathmey Md | Director | 4.00 | $0 |
| Kevin O'Connor Md | Director | 4.00 | $0 |
| Kyle Sell | Director | 4.00 | $0 |
| Paul Strumph Md | Director | 4.00 | $0 |
| Richard J Nowak Md | Director | 4.00 | $0 |
| Todd Fowler | Director (beg 12/25) | 4.00 | $0 |
| Wes Caudle | Director (beg 12/25) | 4.00 | $0 |
| Mark Willig | Director (beg 12/25) | 4.00 | $0 |
| Esther Land | Director (non-voting) | 0.25 | $0 |
| Marcia Lorimer | Director (non-voting) | 0.25 | $0 |
| Mark Kalish | Director (non-voting) | 0.25 | $0 |
| Sam Schuloff | Director (non-voting) | 0.25 | $0 |
| Susan Klinger | Director (non-voting) | 0.25 | $0 |
| Brian Gladden | Director (non-voting) | 0.25 | $0 |
| Samantha Masterson | Chief Executive Officer | 40.00 | $330,105 |
| Craig Stenger | Chief Operating Officer | 40.00 | $193,297 |
| Michael Antonellis | Vice President, Global Marketing and Communication | 40.00 | $172,849 |
| Danielle Kerkovich | Vice President, Global Research | 40.00 | $128,742 |
| Daryl Lee | National Director, Finance | 40.00 | $123,544 |
| Genevieve Mvalo | National Director, Programs | 40.00 | $105,037 |
| Katharine Stober | National Director, Academi | 40.00 | $100,825 |
Nearest by size, location and giving pattern in the database. Geography weighs heavily. Treat it as a starting list, not a ranking of fit.
Form 990 · FY2024 · period ending Dec 31, 2024IRS bulk XML
Filing id 202521219349300047
Form 990 · FY2023 · period ending Dec 31, 2023IRS bulk XML
Filing id 202431309349300808
Form 990 · FY2022 · period ending Dec 31, 2022
Filing id 202301239349300945
Form 990 · FY2021 · period ending Dec 31, 2021
Filing id 202231369349305728
Form 990 · FY2020 · period ending Dec 31, 2020
Filing id 202141979349300614
Form 990 · FY2018 · period ending Dec 31, 2018
Filing id 201912479349301601
Form 990 · FY2017 · period ending Dec 31, 2017
Filing id 201821999349300802
Form 990 · FY2016 · period ending Dec 31, 2016
Filing id 201731989349301398
IRS filings are the source for every fact on this page. Nothing a model writes is ever a source; it can only point at a row here.